Lab
Acupath Laboratories, INC.
Acupath Laboratories, INC. was paid $14.85M by Medicaid between Jan 2018 and Dec 2024, across 31 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 28% of everything it billed.
33Billing provider infoACUPATH LABORATORIES, INC.
PLAINVIEW, NY 11803
PLAINVIEW, NY 11803
33aNPI1215921549assigned 09/01/2005
33bProvider typeClinical Medical Laboratory
28Total paid$14.85M
24GClaims343,159
24DCodes billed31
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#19 of 116
Median peer was paid$618K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,474 | $1.09M | |
| 2019 | 35,095 | $1.47M | |
| 2020 | 36,795 | $1.57M | |
| 2021 | 82,473 | $2.63M | |
| 2022 | 77,118 | $3.42M | |
| 2023 | 50,580 | $2.77M | |
| 2024incomplete | 36,624 | $1.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 28% | 78,935 | 74,651 | $4.16M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 49,317 | 38,020 | $2.59M |
| 88342 | 15% | 47,064 | 43,098 | $2.23M | |
| 88312 | 13% | 38,148 | 37,816 | $1.99M | |
| 88313 | 12% | 45,911 | 43,876 | $1.75M | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.4% | 37,989 | 29,382 | $509K |
| 88121 | 2.7% | 3,527 | 3,200 | $406K | |
| 88341 | 2.2% | 7,430 | 6,993 | $322K | |
| 88112 | 1.2% | 8,199 | 7,107 | $175K | |
| 88120 | <1% | 647 | 453 | $110K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,156 | 6,591 | $103K |
| 88173 | <1% | 3,010 | 2,948 | $103K |
19 more codes
| 88377 | <1% | 381 | $79K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 898 | $76K |
| 88360 | <1% | 2,469 | $71K | |
| 88185 | <1% | 341 | $66K | |
| 88304 | <1% | 2,140 | $33K | |
| 88366 | <1% | 64 | $18K | |
| 88344 | <1% | 195 | $14K | |
| 87220 | <1% | 3,926 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 427 | $9K |
| 88104 | <1% | 498 | $9K | |
| 88189 | <1% | 313 | $5K | |
| 88184 | <1% | 342 | $5K | |
| 88108 | <1% | 323 | $2K | |
| 87631 | <1% | 30 | $2K | |
| 88311 | <1% | 198 | $2K | |
| 88172 | <1% | 64 | $1K | |
| 88177 | <1% | 51 | $647.14 | |
| 85060 | <1% | 123 | $551.13 | |
| 99080 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOX, SHARON (OWNER/PRESIDENT)